XML 70 R48.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaboration and Other Agreements, Gilead (Details) - Gilead [Member] $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jan. 31, 2013 Molecule | Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) | Dec. 31, 2013 USD ($)
Collaboration and Other Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | January 2013 |  |
Recognized revenue under agreement |  | $ 0.0 | $ 5.5 | $ 8.0
Deferred revenue |  | $ 0.0 | 0.0 |
Expected period of development |  | 21 months |  |
Commercialization of molecules | Molecule | 4 |  |  |
License grant fees |  | $ 7.5 |  |
Milestone achieved |  | 0.0 | $ 0.0 |
Maximum [Member] |  |  |  |
Collaboration and Other Agreements [Line Items] |  |  |  |
Additional Potential Pre-Clinical Milestone Payments Under Agreement |  | 20.0 |  |
Additional Potential Clinical, Regulatory And Sales Milestone Payments Under Agreement |  | $ 247.5 |  |

X
- Definition Refers to additional license grant fees under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Total potential clinical, regulatory and sales milestones company could earn under agreement + References No definition available. + Details
Name: | mgnx_AdditionalPotentialClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total potential pre-clinical milestones company could earn under agreement + References No definition available. + Details
Name: | mgnx_AdditionalPotentialPreClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Date on which the Company entered into agreement. + References No definition available. + Details
Name: | mgnx_CollaborationAndOtherAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | invest:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaboration. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=51671726&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |